Ocular Adverse Events after Inactivated COVID-19 Vaccination

• Published in: Vaccines (Basel) Vol. 10; no. 6; p. 918
• Main Authors: Li, Zhihua, Hu, Feng, Li, Qian, Wang, Shuang, Chen, Chunli, Zhang, Yongpeng, Mao, Yu, Shi, Xuehui, Zhou, Haiying, Cao, Xusheng, Peng, Xiaoyan
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 09.06.2022; MDPI
• Subjects: Acuity; adverse event; Adverse events; Age; Coronaviruses; COVID-19; COVID-19 vaccines; Deactivation; Diabetic retinopathy; Diagnosis; Disorders; Immunization; inactivated vaccine; ocular disorder; Pandemics; Patients; Retina; retinal vascular occlusion; Severe acute respiratory syndrome coronavirus 2; Signs and symptoms; Uveitis; Vaccines; Values; Vein & artery diseases; Visual acuity; Beijing China; China; COVID-19; retinal hemorrhage; inactivated vaccine; adverse event; ocular disorder; uveitis; retinal vascular occlusion
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines10060918

Purpose: To report the clinical characteristics of ocular adverse events that have occurred, in China, after vaccination with inactivated COVID-19 vaccines. Methods: A retrospective cross-sectional observational study was conducted of ocular disorders that occurred within 15 days from any dose of an inactivated COVID-19 vaccine. Information on gender, age, the interval between the vaccination and ocular symptoms, laterality, duration of the ocular symptoms, primary visual acuity, and clinical diagnosis were retrospectively collected. Results: Twenty-four patients were involved in the study, including 15 females and 9 males, with a mean age of 41 ± 16 years (range of 8−71 years). The patients all denied a prior history of COVID-19 infection. Ocular adverse events occurred after the first dose of vaccine in 18 patients and, after the second or third doses, in six patients. The interval between vaccination with the inactivated COVID-19 vaccine and ocular symptoms was 6 ± 5 days; six patients were bilaterally involved and 18 patients were unilaterally involved. Regarding the diagnosis, 10 patients were diagnosed with white dot syndrome (WDS), 9 patients were diagnosed with uveitis, and 5 patients were diagnosed with retinal vascular disorders. The ages of patients with WDS were younger than those with uveitis or retinal vascular disorders (32 ± 10 vs. 48 ± 18, p < 0.05). For patients diagnosed with WDS, the best-corrected visual acuity (BCVA) was 0.74 ± 0.73 LogMAR. For patients diagnosed with retinal vascular disorders or uveitis, the BCVA was 1.44 ± 1.26 LogMAR. There was no significant difference (p > 0.05). Conclusions: A relationship cannot be established between inactivated COVID-19 vaccines and ocular disorders; therefore, further investigation of the clinical spectrum of ocular adverse events after vaccination with an inactivated COVID-19 vaccine is necessary.